Charlotte Fletcher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Charlotte Fletcher has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Adam Finn
Bristol University COVID-19 Emergency Research Group , Bristol BS8 1TH , UK
1 shared publication - Adrian J. Mulholland
University of Bristol
1 shared publication - Alexandra Harrison
University of Bristol School of Biochemistry Bristol BS8 1TD , UK
1 shared publication - Andrew D. Davidson
School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK
1 shared publication - Beatriz Vidaña
University of Bristol Bristol Veterinary School Bristol BS40 5DU UK
1 shared publication Bristol UNCOVER Group,
Bristol University COVID-19 Emergency Research Group , Bristol BS8 1TH , UK
1 shared publication
Latest Publications
- Open Access
- 1 October 2023
- Published by Oxford University Press (OUP) in Antibody Therapeutics
- Vol. 6 (4) , 277-297
In vitro generated antibodies guide thermostable ADDomer nanoparticle design for nasal vaccination and passive immunization against SARS-CoV-2
Due to COVID-19, pandemic preparedness emerges as a key imperative, necessitating new approaches to accelerate development of reagents against infectious pathogens. Here, we developed an integrated approach combining synthetic, computational and structural methods with in vitro antibody selection and in vivo immunization to design, produce and validate nature-inspired nanoparticle-based reagents against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Our approach resulted in two innovations: (i) a thermostable nasal vaccine called ADDoCoV, displaying multiple copies of a SARS-CoV-2 receptor binding motif derived epitope and (ii) a multivalent nanoparticle superbinder, called Gigabody, against SARS-CoV-2 including immune-evasive variants of concern (VOCs). In vitro generated neutralizing nanobodies and electron cryo-microscopy established authenticity and accessibility of epitopes displayed by ADDoCoV. Gigabody comprising multimerized nanobodies prevented SARS-CoV-2 virion attachment with picomolar EC50. Vaccinating mice resulted in antibodies cross-reacting with VOCs including Delta and Omicron. Our study elucidates Adenovirus-derived dodecamer (ADDomer)-based nanoparticles for use in active and passive immunization and provides a blueprint for crafting reagents to combat respiratory viral infections.
- 1 October 2023
- Published by Oxford University Press (OUP) in Antibody Therapeutics
- Vol. 6 (4) , 277-297
Open AccessIn vitro generated antibodies guide thermostable ADDomer nanoparticle design for nasal vaccination and passive immunization against SARS-CoV-2
Due to COVID-19, pandemic preparedness emerges as a key imperative, necessitating new approaches to accelerate development of reagents against infectious pathogens. Here, we developed an integrated approach combining synthetic, computational and structural methods with in vitro antibody selection and in vivo immunization to design, produce and validate nature-inspired nanoparticle-based reagents against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Our approach resulted in two innovations: (i) a thermostable nasal vaccine called ADDoCoV, displaying multiple copies of a SARS-CoV-2 receptor binding motif derived epitope and (ii) a multivalent nanoparticle superbinder, called Gigabody, against SARS-CoV-2 including immune-evasive variants of concern (VOCs). In vitro generated neutralizing nanobodies and electron cryo-microscopy established authenticity and accessibility of epitopes displayed by ADDoCoV. Gigabody comprising multimerized nanobodies prevented SARS-CoV-2 virion attachment with picomolar EC50. Vaccinating mice resulted in antibodies cross-reacting with VOCs including Delta and Omicron. Our study elucidates Adenovirus-derived dodecamer (ADDomer)-based nanoparticles for use in active and passive immunization and provides a blueprint for crafting reagents to combat respiratory viral infections.